^
Association details:
| Biomarker: | CD20 expression |
|---|---|
| Cancer: | Lymphoma |
| Drug: | ADI-001 (γδ TCR modulator, CD20-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase 1 study of ADI-001: Anti-CD20 CAR-engineered allogeneic gamma delta (γδ) T cells in adults with B-cell malignancies.
Published date:
05/26/2022
Excerpt:
This phase 1 trial evaluates ADI-001 in adults with relapsed/refractory advanced B-cell lymphoma. Eligibility criteria included presence of measurable lesions, expression of CD20 and ≥ 2 prior systemic therapies….ADI-001 γδ CAR T cells were well tolerated, with a favorable safety profile and encouraging preliminary efficacy.
DOI:
10.1200/JCO.2022.40.16_suppl.7509
Trial ID:
